May 24, 2018
1 min read
May 11, 2018
The Trump Administration’s plans to move Medicare Part B drugs into the Part D system, and to change Part D formulary standards to require a minimum of one drug per category rather than two, would mean additional delays and cost barriers for patients.
1 min read
May 10, 2018
Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.
1 min read
May 9, 2018
Sitting Down With… Cyrus Krakaria, President of Biotechnology at Lupin Limited, Biotech Division, India.
1 min read
May 9, 2018
The immune system scrambles into action when a foreign entity is detected, but not all foreign entities mean harm. New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.
1 min read
May 9, 2018
The sci-fi inspired concern that artificial intelligence will one day rule the world is (mostly) unfounded, but it certainly could have a huge impact on drug discovery.
1 min read
May 9, 2018
1 min read
May 9, 2018
By Bruno Speder, Head Clinical Regulatory Affairs & Consultancy at SGS
1 min read
May 9, 2018
It’s been a long winding journey, but biosimilars are finally starting to shake up the biopharma market. Their true potential remains untapped, however – hindered by market access and myths around safety. Here, four biosimilar gurus discuss successes and tackle the issues head on.
1 min read
